ECSP12012132A - COMBINATION OF THEOBROMINE WITH A DESCONGESTIVE AND ITS USE FOR THE TOS TREATMENT - Google Patents

COMBINATION OF THEOBROMINE WITH A DESCONGESTIVE AND ITS USE FOR THE TOS TREATMENT

Info

Publication number
ECSP12012132A
ECSP12012132A ECSP12012132A ECSP12012132A EC SP12012132 A ECSP12012132 A EC SP12012132A EC SP12012132 A ECSP12012132 A EC SP12012132A EC SP12012132 A ECSP12012132 A EC SP12012132A
Authority
EC
Ecuador
Prior art keywords
theobromine
descongestive
combination
tos
treatment
Prior art date
Application number
Other languages
Spanish (es)
Inventor
John Brew
Robin Mark Bannister
Original Assignee
Biocopea Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocopea Ltd filed Critical Biocopea Ltd
Publication of ECSP12012132A publication Critical patent/ECSP12012132A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un agente comprende teobromina y un descongestivo, como una preparación combinada para el uso simultáneo, secuencial o por separado en terapia, específicamente en la terapia para la tos.An agent comprises theobromine and a decongestant, as a combined preparation for simultaneous, sequential or separate use in therapy, specifically in cough therapy.

ECSP12012132 2009-12-14 2012-06-12 COMBINATION OF THEOBROMINE WITH A DESCONGESTIVE AND ITS USE FOR THE TOS TREATMENT ECSP12012132A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0921805.8A GB0921805D0 (en) 2009-12-14 2009-12-14 Drug composition and its use in therapy
PCT/GB2010/052085 WO2011073646A1 (en) 2009-12-14 2010-12-14 Combination of theobromine with a decongestant and its use for the treatment of cough

Publications (1)

Publication Number Publication Date
ECSP12012132A true ECSP12012132A (en) 2012-09-28

Family

ID=41667045

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012132 ECSP12012132A (en) 2009-12-14 2012-06-12 COMBINATION OF THEOBROMINE WITH A DESCONGESTIVE AND ITS USE FOR THE TOS TREATMENT

Country Status (19)

Country Link
EP (1) EP2512464A1 (en)
JP (2) JP2013513651A (en)
CN (2) CN105816462A (en)
AU (1) AU2010332494B2 (en)
BR (1) BR112012014161A2 (en)
CA (1) CA2784214C (en)
CO (1) CO6541630A2 (en)
EC (1) ECSP12012132A (en)
GB (1) GB0921805D0 (en)
IL (1) IL220383A (en)
MX (1) MX343222B (en)
NZ (1) NZ600243A (en)
PE (1) PE20121537A1 (en)
PH (1) PH12012501203A1 (en)
RU (1) RU2564904C2 (en)
SG (2) SG10201408377QA (en)
UA (1) UA105944C2 (en)
WO (1) WO2011073646A1 (en)
ZA (1) ZA201204293B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314465B2 (en) 2009-06-16 2016-04-19 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
GB0910375D0 (en) 2009-06-16 2009-07-29 Biocopea Ltd Drug composition and its use in therapy
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
US10016437B2 (en) 2009-06-16 2018-07-10 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US9308211B2 (en) 2009-06-16 2016-04-12 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007103A1 (en) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
HUP9700654A2 (en) * 1997-03-26 1999-09-28 Dezső Korbonits Antitussive compositions containing theobromine
US6417206B1 (en) * 2001-01-26 2002-07-09 Medpointe Healthcare Inc. Antitussive/antihist aminic/decongestant compositions
JP2002308761A (en) * 2001-04-09 2002-10-23 Taisho Pharmaceut Co Ltd Cold cough medicine
JP2003128549A (en) * 2001-08-15 2003-05-08 Rohto Pharmaceut Co Ltd Composition applicable to mucous membrane
JP4377564B2 (en) * 2002-05-02 2009-12-02 ロート製薬株式会社 Composition for internal use
RU2311919C2 (en) * 2002-12-30 2007-12-10 Каунсел Оф Сайнтифик Энд Индастриал Рисерч Development of anti-coughing and throat softening herbal composition
US20040202677A1 (en) * 2003-04-10 2004-10-14 Hopkins Kevin J. Method of enhanced regional body fat reduction
US20060153926A1 (en) * 2005-01-10 2006-07-13 Bascom Charles C Compositions, products and methods for controlling weight in a mammal
US20080003280A1 (en) * 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
CN100518775C (en) * 2007-03-16 2009-07-29 邓丽菊 Medicine composition for treating cough and asthma and preparation thereof

Also Published As

Publication number Publication date
CA2784214A1 (en) 2011-06-23
MX2012006625A (en) 2012-10-05
RU2012129839A (en) 2014-01-27
CO6541630A2 (en) 2012-10-16
WO2011073646A1 (en) 2011-06-23
NZ600243A (en) 2013-07-26
EP2512464A1 (en) 2012-10-24
GB0921805D0 (en) 2010-01-27
CN105816462A (en) 2016-08-03
PE20121537A1 (en) 2012-12-21
SG181686A1 (en) 2012-07-30
ZA201204293B (en) 2013-02-27
UA105944C2 (en) 2014-07-10
BR112012014161A2 (en) 2016-05-17
IL220383A0 (en) 2012-08-30
JP2013513651A (en) 2013-04-22
MX343222B (en) 2016-10-28
AU2010332494B2 (en) 2015-01-15
CA2784214C (en) 2018-01-09
PH12012501203A1 (en) 2012-11-05
RU2564904C2 (en) 2015-10-10
JP2016040279A (en) 2016-03-24
AU2010332494A1 (en) 2012-06-14
IL220383A (en) 2017-01-31
CN102740843A (en) 2012-10-17
SG10201408377QA (en) 2015-02-27

Similar Documents

Publication Publication Date Title
CL2013000718A1 (en) An inclusion complex comprising a) a cyclodextrin, b) fulvestrant and c) a carrier; its method of preparation; formulation and dosage form comprising the complex; preparation comprising the complex or formulation; and its use in the treatment of cancer and systemic lupus erythematosus, among other diseases.
CL2009001099A1 (en) Use of a human interleukin-2 mutein for the treatment and / or prevention of an autoimmune disease.
CL2011001811A1 (en) A method of treating a patient who has suffered an acute myocardial infarction that comprises the use of an antifibrotic agent.
CL2015000294A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an epidermal growth factor receptor inhibitor and optionally a pi3halpha inhibitor and use in the treatment of a proliferative disease.
BRPI0914678A8 (en) TOILET DISPENSING DEVICE AND PROCESS FOR DELIVERING A TREATMENT COMPOSITION TO A SANITARY DEVICE
CL2012000248A1 (en) Insulin conjugated compound; preparation procedure; pharmaceutical composition comprising it; pharmaceutical combination; pharmaceutical kit; use in the treatment of insulin-mediated disorders.
CL2012002326A1 (en) Use of a combination of at least one chemotherapeutic agent and an effective amount of an anti-vegf antibody (vascular endothelial growth factor), because it serves to prepare a medicament useful in the treatment of ovarian cancer; and his kit to treat ovarian cancer without prior treatment in a human patient.
CL2015002691A1 (en) Myostatin antagonist in human subjects
BRPI1013698A2 (en) methods for treatment with the use of combination therapy
EA201200484A1 (en) PHARMACEUTICAL COMPOSITION WITH EXISTING SUBSTANCES - METHORMIN AND SYTAGLIPTIN OR VILDAGLIPTIN
CL2013002869A1 (en) A combination containing 2-amino-n- [7-methoxy-8- (3-morpholin-4-ylpropoxy) -2,3-dihydroimidazo [1,2-c] quinazolin-5-yl] pyrimidin-5-carboxamide and abt-737; and its use for the treatment or prophylaxis of breast cancer, in particular inflammatory breast cancer, triple negative breast cancer, her2 receptor positive breast cancer and hormone receptor positive breast cancer.
CO6700840A2 (en) Theobromine in combination with an expectorant or mucolytic for use in therapy
CL2011003327A1 (en) Pharmaceutical composition comprising finafloxacin and an anti-inflammatory agent; use in the treatment of ophthalmic, otic or nasal infections.
PH12012501200A1 (en) Therapeutic combinations of theobromine and an antihistamine
ECSP12012132A (en) COMBINATION OF THEOBROMINE WITH A DESCONGESTIVE AND ITS USE FOR THE TOS TREATMENT
CO6551744A2 (en) COMBINATION OF DRUGS WITH THEOBROMINE AND ITS USE IN THERAPY
CL2012003265A1 (en) Tamarind seed polysaccharide for use in the treatment of infectious diseases; pharmaceutical and / or anti-inflammatory dermocosmetic composition containing said polysaccharide; use of a tamarind seed polysaccharide.
ECSP12011893A (en) COMBINATION OF DRUGS WITH THEOBROMINE AND ITS USE IN THERAPY
ECSP10010661A (en) DRONEDARONE FOR THE PREVENTION OF CARDIOVERSION
CL2010001594A1 (en) Use of nifurtimox to prepare a medicine useful in the treatment of diseases caused by trichomonadide.
ECSP12011951A (en) USE OF A SOURCE OF L3 AND / OR L5 AS A VACCINE OR AS A DIAGNOSIS FOR A PARASITARY DISEASE
CO6480929A2 (en) PROCEDURE FOR USE OF CORTICOTROPINE RELEASE FACTOR FOR CANCER TREATMENT
ES2389424B1 (en) PROCEDURE FOR THE DISPLAY OF SURFACES IN THE HUMAN BODY.
AR061618A1 (en) TEMOZOLOMIDE UNIT DOSAGE FORMS
ECSP12011969A (en) THERAPEUTIC COMBINATIONS OF THEOBROMINE AND AN ANTIHISTAMINE